NEU-723 has been shown in preclinical studies to have strong disease-modifying potential with a higher therapeutic index than other candidates in development
Neuron23 Announces First-in-Human Dose in... - Cure Parkinson's
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinsons Disease
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Not what you're looking for?
You may also like...
Parkinson's Disease Clinical trial for First in Humans use of FGF-1 to treat Parkinson's Disease started by Zhittya Genesis Medicine.
start the First in Humans Proof of Concept-Phase I clinical trial to treat Parkinson's. Daniel...
First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's
https://parkinsonsnewstoday.com/news/first-early-stage-parkinsons-patient-dosed-phase-3-trial-buntan
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
nical-trial-sites-for-the-phase-3-study-of-buntanetap-for-the-treatment-of-parkinsons-disease-301741
Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months
https://www.prnewswire.com/news-releases/annovis-bio-announces-completion-of-phase-iii-parkinsons-di
BREAKTHROUGH I've been waiting YEARS for!
https://scitechdaily.com/new-blood-marker-can-identify-parkinsons-disease/...
Found this article on CBS 
Placebo, the miracle cure
Saffron anti-ininammatory and inhibition of toxic α-Syn protein aggregation
